Clinical Nuclear Medicine最新文献

{"title":"Rare Neoplastic Meningitis in Cerebellar Medulloblastoma Detected by PET/CT.","authors":"Merve Nur Acar Tayyar, Müge Öner Tamam, Kadir Atakir, İbrahim Köprülü, Ayşe Vergili","doi":"10.1097/RLU.0000000000005693","DOIUrl":"10.1097/RLU.0000000000005693","url":null,"abstract":"<p><strong>Abstract: </strong>Neoplastic meningitis, also known as leptomeningeal metastases, is a rare clinical entity seen in less than 1%-2% of primary nervous system tumors. Diagnosis of leptomeningeal metastases is difficult and is achieved by cytologic evidence of malignant cells in cerebrospinal fluid, or demonstration of radiologic abnormality. 18 F-FDG PET/CT can detect leptomeningeal metastases before anatomical changes. In this case, a 42-year-old man with cerebellar medulloblastoma underwent surgery and radiotherapy and had FDG uptake in 3 separate locations after 3 months. The findings indicated leptomeningeal metastases, confirmed by MRI. This highlights the role of 18 F-FDG PET/CT in detecting leptomeningeal disease postmedulloblastoma treatment.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e376-e378"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental Detection of Choroid Plexus Metastasis From Neuroblastoma Demonstrated by 68 Ga-DOTATATE PET/CT.","authors":"Siqi Li, Yanfeng Xu, Xia Lu, Wei Wang, Jigang Yang","doi":"10.1097/RLU.0000000000005672","DOIUrl":"10.1097/RLU.0000000000005672","url":null,"abstract":"<p><strong>Abstract: </strong>An 8-year-old girl with refractory high-risk neuroblastoma underwent 68 Ga-DOTATATE PET/CT to evaluate the feasibility of potential 177 Lu-DOTATATE therapy. The scan showed multiple foci of abnormal 68 Ga-DOTATATE accumulation in the bone region, indicating the presence of bone metastases. Unexpectedly, an abnormal tracer uptake was noted in the left lateral ventricle area. The contrast-enhanced brain MRI showed obvious enhancement of this lesion, suggesting the diagnosis of choroid plexus metastasis. Our case shows that 68 Ga-DOTATATE PET/CT might be useful in diagnosing choroid plexus metastasis.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"531-533"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large Vessel Vasculitis on 18 F-FDG PET/CT in a Patient With Sarcoidosis.","authors":"Raksha Kulkarni, Sampanna Jung Rayamajhi, Vipashyana Jadav, Rahman Akinlusi, Nasrin Ghesani","doi":"10.1097/RLU.0000000000005762","DOIUrl":"10.1097/RLU.0000000000005762","url":null,"abstract":"<p><p>Large vessel vasculitis is a rarely reported finding in patients with sarcoidosis. 18 F-FDG PET/CT is an effective modality in detecting active sites of inflammation in sarcoidosis. We present a case of systemic sarcoidosis where 18 F-FDG PET/CT incidentally detected a rare finding of sarcoid-associated large vessel vasculitis along with cardiac and pulmonary sarcoidosis.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e383-e387"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple Myeloma.","authors":"Niklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, Leo Rasche, Takahiro Higuchi, Samuel Samnick, Constantin Lapa, Hermann Einsele, Sebastian E Serfling, Andreas K Buck, Rudolf A Werner","doi":"10.1097/RLU.0000000000005813","DOIUrl":"https://doi.org/10.1097/RLU.0000000000005813","url":null,"abstract":"<p><strong>Background: </strong>Markedly expressed on hematopoietic stem cells, C-X-C motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) has been used in relapsed/refractory (r/r) MM to prepare for hematopoietic stem cell transplantation (HSCT). We aimed to determine the myeloablative efficacy of CXCR4 RLT in MM patients and assessed the safety profile of this treatment.</p><p><strong>Methods: </strong>Thirty-eight patients with r/r MM were treated with 40 cycles of CXCR4-targeting [ 90 Y]Y-PentixaTher or [ 177 Lu]Lu-PentixaTher. Myeloablative dynamics were closely monitored by examining hematologic parameters before the application of RLT (day 1), on day 2, and on the start day of conditioning chemotherapy (CON, median day 10). Laboratory parameters evaluating organ toxicity were collected and categorized following the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Cairo-Bishop classification was also applied to identify patients experiencing laboratory tumor lysis syndrome (TLS) caused by RLT. After CON, we determined the rate of patients receiving hematopoietic stem cell transplantation (HSCT) followed by successful neutrophile engraftment.</p><p><strong>Results: </strong>Forty cycles of CXCR4-directed RLT were applied. Myeloablative effects resulted in an 81.8% decline in leukocytes and a 69.4% decrease in neutrophil levels till the day of CON ( P <0.0001, respectively), followed by platelets (63.1%; P <0.0001) and hemoglobin (9%; P =0.002). We observed 58 AE Events (1/58 [1.7%], ≥ grade 3). CON could be applied successfully after 39/40 (97.5%) cycles. After CON, in 39/39 (100%) of the cycles, HSCT was conducted, and successful neutrophil engraftment was reached after 37/39 (94.9%) of these cycles.</p><p><strong>Conclusions: </strong>CXCR4-directed RLT exerted relevant myeloablative effects. When performing HSCT after applying additional CON, successful neutrophile engraftment was reached in the vast majority of the cases.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 6","pages":"495-500"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remarkable 99mTc-FAPI-46 Uptake in a Patient With Anaplastic Thyroid Carcinoma: A Promising Step in Theranostic Field.","authors":"Mitra Ghahraman, Pegah Sahafi, Mohammad Hadi Samadi, Kamran Aryana, Atena Aghaee","doi":"10.1097/RLU.0000000000005746","DOIUrl":"10.1097/RLU.0000000000005746","url":null,"abstract":"<p><p>Fibroblast activation protein (FAP)-targeted radionuclides are known as a promising step in cancer diagnosis and treatment (theranostic), although it is still a subject under investigation. We present a patient with anaplastic thyroid carcinoma who underwent 99mTc-FAPI-46 SPECT/CT for the evaluation of metastatic disease. Several metastatic sites were found with considerable 99mTc-FAPI-46 uptake. Malignant FAPI uptake was observed in the large calcified thyroid mass, mediastinal lymph node, both lungs, liver, few skeletal sites, and around knees prostheses. Given the notable uptake of lesions, the patient was considered as a candidate for FAP-targeted radionuclide therapy.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e365-e367"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Volumetric Parameters on Pretreatment FDG PET/CT in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Therapy.","authors":"Jeong Won Lee, Sang Mi Lee, Beodeul Kang, Jung Sun Kim, Chansik An, Hong Jae Chon, Su Jin Jang","doi":"10.1097/RLU.0000000000005896","DOIUrl":"https://doi.org/10.1097/RLU.0000000000005896","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to assess prognostic significance of FDG PET/CT parameters in predicting progression-free survival (PFS) and overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab therapy.</p><p><strong>Patients and methods: </strong>We retrospectively enrolled 78 patients with HCC who underwent FDG PET/CT before atezolizumab plus bevacizumab therapy and identified intrahepatic target tumor lesions on pretreatment imaging studies. From PET/CT images, we measured SUVmax, tumor-to-normal liver uptake ratio, metabolic tumor volume, and total lesion glycolysis (TLG) for intrahepatic tumor lesions, as well as SUVmax for extrahepatic metastatic lesions (extrahepatic SUVmax).</p><p><strong>Results: </strong>In comparisons of PET/CT parameters, patients with progressive disease demonstrated significantly higher TLG values than those achieving complete or partial response ( P < 0.05). In the multivariate survival analysis, TLG independently predicted both PFS ( P = 0.019) and OS ( P = 0.003). Metabolic tumor volume was significantly associated with OS alone ( P = 0.010), and extrahepatic SUVmax was significantly associated with only PFS ( P = 0.045). Patients with high TLG values experienced poorer PFS and OS than those with low TLG values ( P < 0.05).</p><p><strong>Conclusions: </strong>TLG in intrahepatic HCC lesions was significantly associated with treatment response and served as an independent prognostic factor for PFS and OS. TLG could be a potential imaging biomarker for predicting clinical outcomes in patients with HCC receiving atezolizumab plus bevacizumab therapy.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 6","pages":"486-494"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brown Tumor Induced by Hyperparathyroidism Detected by 68Ga-FAPI-04 PET/CT.","authors":"Zeyu Zhang, Yunshuo Zhang, Ye Peng, Changjing Zuo, Chao Cheng","doi":"10.1097/RLU.0000000000005772","DOIUrl":"https://doi.org/10.1097/RLU.0000000000005772","url":null,"abstract":"<p><p>A 50-year-old woman presented with persistent left hip pain. MRI suggested metastatic lesions or hematologic disease. Further evaluation with 68Ga-FAPI-04 PET/CT revealed multiple skeletal lesions with radiotracer uptake and a non-avid low-density mass in the right parathyroid area. Elevated parathyroid hormone, hypercalcemia, and a 99mTc-sestamibi-avid right parathyroid mass led to a diagnosis of right parathyroid adenoma causing secondary brown tumors. Surgical removal of the parathyroid mass confirmed the diagnosis, highlighting the efficacy of 68Ga-FAPI-04 PET imaging in detecting brown tumors.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 6","pages":"547-548"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intranodular Thyroid Metastasis of a Large Cell Neuroendocrine Carcinoma of the Endometrium.","authors":"Capucine Richard, Abir Al Ghuzlan, Virginie Huchet, Vincent Cockenpot, Ségolène Hescot","doi":"10.1097/RLU.0000000000005665","DOIUrl":"10.1097/RLU.0000000000005665","url":null,"abstract":"<p><strong>Abstract: </strong>A 64-year-old woman underwent initial 18 F-FDG PET/CT staging for a suspicious endometrial mass, which showed high uptake in the endometrial mass and a focal uptake in a known left thyroid nodule. Histology revealed a high-grade large cell neuroendocrine carcinoma of the endometrium with FIGO (International Federation of Gynecology and Obstetrics) stage Ib. Further explorations revealed a synchronous thyroid metastasis. Patient then received adjuvant immunochemotherapy. This case showed a potential pitfall in the initial assessment of this rare and aggressive malignancy on which the therapeutic approach greatly depends.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e388-e390"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.","authors":"Jingjing Zhang, Deling Li, Mengqi Shi, Vivianne Jakobsson, Wang Jia, Harshad R Kulkarni, Christiane Schuchardt, Richard P Baum","doi":"10.1097/RLU.0000000000005845","DOIUrl":"https://doi.org/10.1097/RLU.0000000000005845","url":null,"abstract":"<p><strong>Background: </strong>Peptide receptor radionuclide therapy (PRRT) offers a promising treatment option by targeting the high density of somatostatin receptors overexpressed in meningiomas. The objective of this study aimed to evaluate the long-term outcome of PRRT in patients with refractory meningioma.</p><p><strong>Patients and methods: </strong>Eighteen patients with refractory meningioma, presenting with progression or recurrence despite surgery or radiotherapy or having inoperable tumors and lack of other therapeutic options, received PRRT with 177Lu-labeled or 90Y-labeled somatostatin analogs (DOTATATE, DOTATOC, or HA-DOTATATE) between January 2004 and December 2019. Treatment response was evaluated according to the Response Assessment in Neuro-Oncology, Response Evaluation Criteria in Solid Tumors, and molecular imaging criteria.</p><p><strong>Results: </strong>Most patients received 2 cycles of PRRT, and up to 4 cycles were applied. The mean total administered activity was 12.7 GBq (range: 8.5-28.5 GBq). Of 14 patients monitored after 2 cycles of PRRT, disease control was reached in 12 (85.7%) patients. The median progression-free survival was 32.3 months, and the median OS has yet to be reached with a median follow-up of 67.1 months. All patients tolerated the therapy without any serious acute adverse effects. No Common Terminology Criteria for Adverse Event grades 2-4 anemia, leukopenia, or thrombocytopenia toxicities were observed during or after PRRT. No renal toxicity, hepatotoxicity, or late radiation adverse effects were reported during long-term follow-up.</p><p><strong>Conclusions: </strong>PRRT showed promising outcomes in patients with refractory meningiomas, with high disease control and encouraging progression-free survival and OS, and therefore appears to be a favorable therapeutic option. With long-term follow-up, PRRT demonstrated a favorable safety profile, resulting in very few side effects in this cohort of patients with meningioma.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 6","pages":"508-516"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bisphosphonate Bone Imaging Agent [68Ga]Ga-P15-041 for Evaluating Skeletal Metastases in Prostate Cancer: A Comparison With [68Ga]Ga-PSMA-11 PET/CT.","authors":"Jiarou Wang, Linlin Li, Tianrui Feng, Rongxi Wang, Jialin Xiang, Yaping Luo, Lin Zhu, Hank F Kung, Weigang Yan, Zhaohui Zhu","doi":"10.1097/RLU.0000000000005883","DOIUrl":"https://doi.org/10.1097/RLU.0000000000005883","url":null,"abstract":"<p><strong>Background: </strong>Accurate diagnosis of bone metastases in prostate cancer is essential for staging, prognosis, and treatment. Although PSMA PET/CT is highly effective, complementary imaging is needed to clarify indeterminate lesions. The novel bisphosphonate-based agent [68Ga]Ga-P15-041 shows superior diagnostic accuracy over conventional SPECT imaging, indicating its potential as an auxiliary diagnostic tool. This study explores its role in detecting and assessing prostate cancer bone metastases.</p><p><strong>Patients and methods: </strong>This prospective study enrolled 35 patients with prostate cancer and skeletal metastases, who underwent both [68Ga]Ga-P15-041 and [68Ga]Ga-PSMA-11 PET/CT within 1 week. Lesions detected by [68Ga]Ga-PSMA-11 PET/CT were classified using Prostate-specific Membrane Antigen Reporting and Data System 2.0.</p><p><strong>Results: </strong>[68Ga]Ga-P15-041 PET/CT detected more lesions than [68Ga]Ga-PSMA-11 PET/CT (525 vs 509, P < 0.001) and demonstrated significantly higher tracer uptake, with a mean SUV of 20.73 ± 14.67 compared with 11.13 ± 8.12 (P < 0.0001). It detected significantly more osteoblastic lesions (504 vs 391, P < 0.0001). In addition, this study established the Reporting and Data System for [68Ga]Ga-P15-041 (P15-041-RADS), which classifies prostate cancer bone metastases into 5 categories based on SUVmax and morphologic changes. P15-041-RADS reclassified 85.71% of Prostate-specific Membrane Antigen Reporting and Data System category 3 lesions and 95.00% of 5T lesions into higher-confidence categories, offering improved diagnostic clarity. Limitations include small sample size and lack of pathologic gold standards.</p><p><strong>Conclusions: </strong>[68Ga]Ga-P15-041 PET/CT is a promising and accessible bone imaging agent that could complement [68Ga]Ga-PSMA-11 PET/CT in the diagnosis and classification of bone metastases in prostate cancer.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 6","pages":"517-522"},"PeriodicalIF":9.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}